title: Dominant negative activity of mutant thyroid hormone alpha1 receptors from patients with hepatocellular carcinoma.
abstract: Complementary DNAs for two mutant thyroid hormone alpha1 receptors (TR alpha1) were isolated from hepatocellular carcinomas of two patients. Sequence analyses of the complementary DNAs showed a single Val390Ala and double Pro398Ser/Glu350Lys mutations in mutants H and L, respectively. We characterized their hormone-binding, DNA-binding, and dominant negative activities. Mutants H and L did not bind the hormone T3. Their DNA-binding activities were analyzed using three types of thyroid hormone response elements (TREs) in which the half-site binding motifs are arranged in an everted repeat (Lys), an inverted repeat (Pal), or a direct repeat separated by four nucleotides (DR4). Compared with wild-type TR alpha1 (w-TR alpha1), which bound these TREs with different homodimer/monomer ratios, binding of mutant L to the three TREs as homodimers was reduced by approximately 90%. However, binding of mutant H to these TREs was more complex. Although it bound normally to DR4 as homodimers, its binding to Lys as homodimers was reduced by approximately 80%. Surprisingly, its binding to Pal was markedly enhanced compared with w-TR alpha1. The binding of these two mutants to the three TREs as heterodimers with retinoid X receptors (RXR alpha and -beta) was not significantly affected. Consistent with the lack of T3-binding activity, both mutants had lost their trans-activation capacity. Mutants H and L exhibited dominant negative activity, but differed in their TRE dependency. The dominant negative potency of mutant H was in the rank order of Pal > DR4 > Lys, whereas no TRE dependency was observed for mutant L. The present study indicates that mutations of the TR alpha gene do occur in patients and that these novel TR alpha1 mutants provide a valuable tool to further understand the molecular basis of the dominant negative action of mutant TRs.
authors.affiliation: Department of Biochemistry, Chang-Gung College of Medicine and Technology, Taoyuan, Taiwan. cguaplo.cgu.tw.edu.
authors.forename: K H
authors.initials: KH
authors.lastname: Lin
authors.forename: X G
authors.initials: XG
authors.lastname: Zhu
authors.forename: H C
authors.initials: HC
authors.lastname: Hsu
authors.forename: S L
authors.initials: SL
authors.lastname: Chen
authors.forename: H Y
authors.initials: HY
authors.lastname: Shieh
authors.forename: S T
authors.initials: ST
authors.lastname: Chen
authors.forename: P
authors.initials: P
authors.lastname: McPhie
authors.forename: S Y
authors.initials: SY
authors.lastname: Cheng
mesh_terms: D001483:Base Sequence; D006528:Carcinoma, Hepatocellular / Q000235:genetics*; D003001:Cloning, Molecular; D004268:DNA-Binding Proteins / Q000378:metabolism; D005799:Genes, Dominant; D006801:Humans; D008113:Liver Neoplasms / Q000235:genetics*; D008297:Male; D017354:Point Mutation; D011988:Receptors, Thyroid Hormone / Q000235:genetics*; D015533:Transcriptional Activation / Q000502:physiology; D014284:Triiodothyronine / Q000378:metabolism
chemical_list: D004268:DNA-Binding Proteins; D011988:Receptors, Thyroid Hormone; D014284:Triiodothyronine